Welcome!

News Feed Item

Spina Bifida Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Spina Bifida Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280944/Spina-Bifida-Global-Clinical-Trials-Review-H2-2014.html

Spina Bifida Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Spina Bifida Global Clinical Trials Review, H2, 2014" provides data on the Spina Bifida clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Spina Bifida. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Spina Bifida. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Spina Bifida 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Central and South America 12
Clinical Trials by G7 Countries: Proportion of Spina Bifida to Central Nervous System Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Spina Bifida to Central Nervous System Clinical Trials 16
Clinical Trials by Phase 17
In Progress Trials by Phase 18
Clinical Trials by Trial Status 19
Clinical Trials by End Point Status 20
Unaccomplished Trials of Spina Bifida 21
Subjects Recruited Over a Period of Time 22
Clinical Trials by Sponsor Type 23
Prominent Sponsors 24
Prominent Drugs 25
Clinical Trial Profiles 26
Clinical Trial Overview of Top Companies 26
Tengion, Inc. 26
Clinical Trial Overview of Tengion, Inc. 26
Clinical Trial Overview of Top Institutes / Government 27
Eunice Kennedy Shriver National Institute of Child Health and Human Development 27
Clinical Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human Development 27
Centers for Disease Control and Prevention 28
Clinical Trial Overview of Centers for Disease Control and Prevention 28
William Beaumont Hospitals 29
Clinical Trial Overview of William Beaumont Hospitals 29
Aarhus University 30
Clinical Trial Overview of Aarhus University 30
Rennes University Hospital 31
Clinical Trial Overview of Rennes University Hospital 31
Baylor College of Medicine 32
Clinical Trial Overview of Baylor College of Medicine 32
UMC Utrecht Holding BV 33
Clinical Trial Overview of UMC Utrecht Holding BV 33
Universitaire Ziekenhuizen Leuven 34
Clinical Trial Overview of Universitaire Ziekenhuizen Leuven 34
University of New Mexico 35
Clinical Trial Overview of University of New Mexico 35
Duke University 36
Clinical Trial Overview of Duke University 36
Five Key Clinical Profiles 37
Appendix 56
Abbreviations 56
Definitions 56
Research Methodology 57
Secondary Research 57
About GlobalData 58
Contact Us 58
Disclaimer 58
Source 58

List of Tables

Spina Bifida Therapeutics, Global, Clinical Trials by Region, 2014* 6
Spina Bifida Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Spina Bifida Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Spina Bifida Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Spina Bifida Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 10
Spina Bifida Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Spina Bifida Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 12
Proportion of Spina Bifida to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Spina Bifida Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Spina Bifida Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Spina Bifida to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Spina Bifida Therapeutics, Global, Clinical Trials by Phase, 2014* 17
Spina Bifida Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 18
Spina Bifida Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Spina Bifida Therapeutics Clinical Trials, Global, by End Point Status, 2014* 20
Spina Bifida Therapeutics, Global, Withdrawn Clinical Trials, 2014* 21
Spina Bifida Therapeutics, Global, Terminated Clinical Trials, 2014* 21
Spina Bifida Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Spina Bifida Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 23
Spina Bifida Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 24
Spina Bifida Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 25
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Tengion, Inc., 2014* 26
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2014* 27
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Centers for Disease Control and Prevention, 2014* 28
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by William Beaumont Hospitals, 2014* 29
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Aarhus University, 2014* 30
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Rennes University Hospital, 2014* 31
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Baylor College of Medicine, 2014* 32
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by UMC Utrecht Holding BV, 2014* 33
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Universitaire Ziekenhuizen Leuven, 2014* 34
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by University of New Mexico, 2014* 35
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014* 36

List of Figures

Spina Bifida Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Spina Bifida Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Spina Bifida Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Spina Bifida Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 10
Proportion of Spina Bifida to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Spina Bifida Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Spina Bifida Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Spina Bifida to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Spina Bifida Therapeutics, Global, Clinical Trials by Phase (%), 2014* 17
Spina Bifida Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 18
Spina Bifida Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Spina Bifida Therapeutics Clinical Trials, Global, by End Point Status, 2014* 20
Spina Bifida Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Spina Bifida Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 23
GlobalData Methodology 57

To order this report: Spina Bifida Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280944/Spina-Bifida-Global-Clinical-Trials-Review-H2-2014.html

__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
You have great SaaS business app ideas. You want to turn your idea quickly into a functional and engaging proof of concept. You need to be able to modify it to meet customers' needs, and you need to deliver a complete and secure SaaS application. How could you achieve all the above and yet avoid unforeseen IT requirements that add unnecessary cost and complexity? You also want your app to be responsive in any device at any time. In his session at 19th Cloud Expo, Mark Allen, General Manager of...
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
Get deep visibility into the performance of your databases and expert advice for performance optimization and tuning. You can't get application performance without database performance. Give everyone on the team a comprehensive view of how every aspect of the system affects performance across SQL database operations, host server and OS, virtualization resources and storage I/O. Quickly find bottlenecks and troubleshoot complex problems.
"Coalfire is a cyber-risk, security and compliance assessment and advisory services firm. We do a lot of work with the cloud service provider community," explained Ryan McGowan, Vice President, Sales (West) at Coalfire Systems, Inc., in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service. In his session at 19th Cloud Exp...
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain. In this power panel at @...
Major trends and emerging technologies – from virtual reality and IoT, to Big Data and algorithms – are helping organizations innovate in the digital era. However, to create real business value, IT must think beyond the ‘what’ of digital transformation to the ‘how’ to harness emerging trends, innovation and disruption. Architecture is the key that underpins and ties all these efforts together. In the digital age, it’s important to invest in architecture, extend the enterprise footprint to the cl...
Bert Loomis was a visionary. This general session will highlight how Bert Loomis and people like him inspire us to build great things with small inventions. In their general session at 19th Cloud Expo, Harold Hannon, Architect at IBM Bluemix, and Michael O'Neill, Strategic Business Development at Nvidia, discussed the accelerating pace of AI development and how IBM Cloud and NVIDIA are partnering to bring AI capabilities to "every day," on-demand. They also reviewed two "free infrastructure" pr...
Fact: storage performance problems have only gotten more complicated, as applications not only have become largely virtualized, but also have moved to cloud-based infrastructures. Storage performance in virtualized environments isn’t just about IOPS anymore. Instead, you need to guarantee performance for individual VMs, helping applications maintain performance as the number of VMs continues to go up in real time. In his session at Cloud Expo, Dhiraj Sehgal, Product and Marketing at Tintri, sha...
Whether your IoT service is connecting cars, homes, appliances, wearable, cameras or other devices, one question hangs in the balance – how do you actually make money from this service? The ability to turn your IoT service into profit requires the ability to create a monetization strategy that is flexible, scalable and working for you in real-time. It must be a transparent, smoothly implemented strategy that all stakeholders – from customers to the board – will be able to understand and comprehe...
CloudJumper, a Workspace as a Service (WaaS) platform innovator for agile business IT, has been recognized with the Customer Value Leadership Award for its nWorkSpace platform by Frost & Sullivan. The company was also featured in a new report(1) by the industry research firm titled, “Desktop-as-a-Service Buyer’s Guide, 2016,” which provides a comprehensive comparison of DaaS providers, including CloudJumper, Amazon, VMware, and Microsoft.
Businesses and business units of all sizes can benefit from cloud computing, but many don't want the cost, performance and security concerns of public cloud nor the complexity of building their own private clouds. Today, some cloud vendors are using artificial intelligence (AI) to simplify cloud deployment and management. In his session at 20th Cloud Expo, Ajay Gulati, Co-founder and CEO of ZeroStack, will discuss how AI can simplify cloud operations. He will cover the following topics: why clou...
"Dice has been around for the last 20 years. We have been helping tech professionals find new jobs and career opportunities," explained Manish Dixit, VP of Product and Engineering at Dice, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"Qosmos has launched L7Viewer, a network traffic analysis tool, so it analyzes all the traffic between the virtual machine and the data center and the virtual machine and the external world," stated Sebastien Synold, Product Line Manager at Qosmos, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.